JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Investment demonstrates confidence in America’s commitment to science and innovation
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Subscribe To Our Newsletter & Stay Updated